Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors
ChemMedChem · 25.02.2026 · 21 (4)
DOI: 10.1002/cmdc.202500879 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 21.12.2025. Verfasst von Giovanna Pitasi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno D'Alcontres 31, I-98125, Messin…. Hauptthemen laut MEDLINE: Pancreatic Elastase, Benzimidazoles, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Catholic University of Pusan, Ministry of Education, University and Research.
Abstract (Originalsprache)
Human elastase 1 has been shown to possess an important role in maintaining skin stability and elasticity through the proteolytic cleavage of elastin (ELN), a hydrophobic protein that serves as a key component of extracellular matrix in the skin. The development of antielastase agents represents a promising therapeutic approach for treating skin pathologies characterized by elastin degradation, with applications in both dermatology and cosmetology. Reversible inhibitors represent a therapeutic strategy, offering selective inhibition of elastase proteolytic activity while preserving the function of other physiologically essential serine proteases. Using porcine pancreatic elastase (PPE) as a well‐established surrogate of human skin elastase, a focused series of noncovalent inhibitors designed to bind the catalytic area of PPE is assayed. Several compounds display an antielastase activity, including N ‐(2‐bromophenyl)‐2‐(6‐chloro‐1‐(3,5‐dimethylbenzyl)‐1 H ‐benzo[d]imidazol‐2‐ylthio)acetamide ( 7 ) that exhibits the most potent inhibitory effects (IC 50 = 41.1 µM), similar to standard compound oleanolic acid (IC 50 value of 25.7 µM). The observed structure–activity relationship is further validated through molecular docking and dynamic studies, which provide mechanistic understanding of the binding interactions and establish suggestions for further rational drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno D'Alcontres 31, I-98125, Messina, Italy.
- Department of Life and Environment Sciences, University of Cagliari, I-09042, Monserrato, Cagliari, Italy.
ORCID-Profile: Laura De Luca
Förderung
- Ministero dell'Università e della Ricerca
- Catholic University of Pusan
- Ministry of Education, University and Research
- CUP
Zitieren
APA
Pitasi, G., Floris, S., Mancuso, F., Savoca, G., Gitto, R., Fais, A., & De Luca, L. (2026). Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors. ChemMedChem, 21(4). https://doi.org/10.1002/cmdc.202500879
Vancouver
Pitasi G, Floris S, Mancuso F, Savoca G, Gitto R, Fais A, et al. Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors. ChemMedChem. 2026;21(4). doi:10.1002/cmdc.202500879
BibTeX
@article{Pitasi2026,
author = {Pitasi, Giovanna and Floris, Sonia and Mancuso, Francesca and Savoca, Giulia and Gitto, Rosaria and Fais, Antonella and De Luca, Laura},
title = {Investigating the Ligand‐Binding Properties of N‐arylbenzimidazoles as Novel Elastase Inhibitors},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {4},
doi = {10.1002/cmdc.202500879}
}
EUVIMED